Retatrutide: FDA records on compounded and unapproved products

Has FDA taken action on compounded retatrutide?

Yes. As of Nov 15, 2026, FDA has issued 21 warning letters to 21 companies whose text names retatrutide, the latest dated Aug 24, 2026, and openFDA lists 1 recall report naming it. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs (FDA page current as of Oct 1, 2026).

As of Nov 15, 2026, FDA’s drug shortage data lists no retatrutide products.

What FDA has stated, by date

FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.

FDA drug shortage status

No retatrutide entries in FDA’s drug shortage data as of Nov 15, 2026.

Active ingredient (API) imports: FDA import alert and refusal records

FDA’s Import Alert 66-80 Green List (published Oct 9, 2026) has no entry naming retatrutide. FDA’s import refusal records list 11 refused shipment lines whose product code names retatrutide, from Jul 24, 2026 to Oct 13, 2026, most often from Canada (3), Vietnam (3) and China (2); 0 carry an API or powder product code listed on the alert.

Refused retatrutide lines by country and form

Canada3
Vietnam3
China2
Lithuania1
Poland1
Switzerland1
Code not listed on Import Alert 66-8011

Most recent refused retatrutide lines

Shipment ID
Oct 13, 2026UAB LABOCHEMA LTLithuania61PIP78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-801FX-0240047-2/10002/1A
Oct 7, 2026SHANGHAI SHUNYI TRADE CO LTDChina61PIR78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80XXX-0763321-9/1/2
Oct 7, 2026XU LIHUA JINGFANG Trading Co. LTDChina61PIR78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80XXX-0763336-3/1/1
Oct 2, 2026MetaTide HealthcareSwitzerland61PCK78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80XXX-0759691-4/1/1
Sep 24, 2026COMEM NATURAL JSCVietnam61PDZ78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-801FX-2060079-8/20002/1D
Sep 24, 2026COMEM NATURAL JSCVietnam61PDZ78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-801FX-2060079-8/20002/1H
Sep 24, 2026COMEM NATURAL JSCVietnam61PDZ78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-801FX-2060079-8/20002/1I
Aug 25, 2026N EDGE GROUP INCCanada61PCY78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-801FX-1683942-6/10002/1
Aug 25, 2026N EDGE GROUP INCCanada61PCY78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-801FX-1683962-4/10002/1
Aug 25, 2026N EDGE GROUP INCCanada61PCY78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-801FX-1684201-6/10002/1
Jul 24, 2026Name not shownPoland61PCY78 RETATRUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-801FX-3061901-9/10002/1

All firms and countries: Firms on GLP-1 import records.

FDA NDC Directory listings

FDA’s NDC Directory files read Nov 15, 2026 carry 11 listings naming retatrutide: BULK INGREDIENT (10); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (1). Every listing: GLP-1 listings in FDA’s NDC Directory. FDA says an NDC “does not in any way denote FDA approval of the product.”

Medicare and Medicaid spending on retatrutide

CMS’s Medicare Part D Spending by Drug file (2020 to 2024) and Medicaid State Drug Utilization Data (2020 to 2026), read Nov 15, 2026, were searched for retatrutide by generic and product name; neither lists a product under that name. Other GLP-1 drugs: Medicare and Medicaid spending on GLP-1 drugs.

FDA warning letters naming retatrutide

Later letters FDA listsLetter
Aug 24, 2026TXP Innovations LLC dba Tex PeptidesUnapproved New Drugs/MisbrandedSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026Royal Peptides LLCUnapproved New Drugs/MisbrandedSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026NuScience Peptides LLCUnapproved New Drugs/MisbrandedSemaglutide, Retatrutide, Survodutide, MazdutideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026Peptide Partners LLCUnapproved New Drugs/MisbrandedSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Aug 24, 2026Peak Performance PeptidesUnapproved New Drugs/MisbrandedSemaglutide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Mar 31, 2026Prime SciencesUnapproved New Drugs Sold Over the InternetSemaglutide, Tirzepatide, Retatrutide, Cagrilintide, MazdutideNone listed by FDA as of Nov 15, 2026fda.gov
Mar 31, 2026Mile High Compounds LLCUnapproved New Drugs Sold Over the InternetSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Mar 31, 2026Lovega LLC dba Pink Pony PeptidesUnapproved New Drugs Sold Over the InternetTirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Mar 31, 2026Gram PeptidesUnapproved New Drugs Sold Over the InternetTirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Jan 20, 2026GenoGenix LLCCompounding Pharmacy/Adulterated Drug ProductsSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Dec 8, 2025Darmerica, LLCCGMP/Active Pharmaceutical Ingredient (API)/Adulterated/MisbrandedRetatrutide, CagrilintideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 9, 2025Amazing MedsUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)Semaglutide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 9, 2025GenLabMedsUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)Semaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 9, 2025MedClub by Dr. JennUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)Semaglutide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 9, 2025GLP-1 SolutionUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)Semaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 9, 2025ASN-LABSUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)Semaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Sep 9, 2025EA WORKS Limited Liability Company dba Trust LabsUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)Semaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Dec 10, 2024Prime Vitality, Inc. dba Prime PeptidesUnapproved New Drugs/MisbrandedSemaglutide, Tirzepatide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Dec 10, 2024SwisschemsUnapproved New Drugs/MisbrandedSemaglutide, RetatrutideNone listed by FDA as of Nov 15, 2026fda.gov
Dec 10, 2024Xcel Research LLCUnapproved New Drugs/MisbrandedSemaglutide, Retatrutide, Cagrilintide, Survodutide, MazdutideNone listed by FDA as of Nov 15, 2026fda.gov
Dec 10, 2024Summit Research PeptidesUnapproved New Drugs/MisbrandedSemaglutide, Tirzepatide, Retatrutide, Cagrilintide, MazdutideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

Recalls naming retatrutide

Record
Jul 30, 2025GenoGenix LLCRetatrutide for Injection, 60mg / 10mL vial, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692Lack of Assurance of SterilityClass IIOngoingD-0093-2026

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.